SK738982A3 - Human immune interferon and derivative thereof, dna-fragment, replicable expression vector, a recombinant microorganism or a cell culture, pharmaceutical composition and use thereof - Google Patents

Human immune interferon and derivative thereof, dna-fragment, replicable expression vector, a recombinant microorganism or a cell culture, pharmaceutical composition and use thereof Download PDF

Info

Publication number
SK738982A3
SK738982A3 SK7389-82A SK738982A SK738982A3 SK 738982 A3 SK738982 A3 SK 738982A3 SK 738982 A SK738982 A SK 738982A SK 738982 A3 SK738982 A3 SK 738982A3
Authority
SK
Slovakia
Prior art keywords
human immune
immune interferon
dna
interferon
amino acid
Prior art date
Application number
SK7389-82A
Other languages
English (en)
Slovak (sk)
Other versions
SK279535B6 (sk
Inventor
David V Goeddel
Patrick W Gray
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK738982(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SK279535B6 publication Critical patent/SK279535B6/sk
Publication of SK738982A3 publication Critical patent/SK738982A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK7389-82A 1981-10-19 1982-10-18 Human immune interferon and derivative thereof, dna-fragment, replicable expression vector, a recombinant microorganism or a cell culture, pharmaceutical composition and use thereof SK738982A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31248981A 1981-10-19 1981-10-19

Publications (2)

Publication Number Publication Date
SK279535B6 SK279535B6 (sk) 1998-12-02
SK738982A3 true SK738982A3 (en) 1998-12-02

Family

ID=23211703

Family Applications (1)

Application Number Title Priority Date Filing Date
SK7389-82A SK738982A3 (en) 1981-10-19 1982-10-18 Human immune interferon and derivative thereof, dna-fragment, replicable expression vector, a recombinant microorganism or a cell culture, pharmaceutical composition and use thereof

Country Status (43)

Country Link
US (4) US4762791A (enExample)
EP (1) EP0077670B1 (enExample)
JP (3) JPS5890514A (enExample)
KR (1) KR840001837A (enExample)
AT (1) ATE44289T1 (enExample)
AU (1) AU561343B2 (enExample)
BG (2) BG44877A3 (enExample)
BR (1) BR8206068A (enExample)
CA (1) CA1341590C (enExample)
CH (1) CH663619A5 (enExample)
CZ (1) CZ282154B6 (enExample)
DD (1) DD208822A5 (enExample)
DE (4) DE19375065I2 (enExample)
DK (1) DK163187C (enExample)
DZ (1) DZ467A1 (enExample)
ES (1) ES516620A0 (enExample)
FI (1) FI86559C (enExample)
FR (1) FR2514783B1 (enExample)
GB (1) GB2107718B (enExample)
GR (1) GR78391B (enExample)
GT (1) GT198277746A (enExample)
HK (1) HK66289A (enExample)
HU (1) HU202287B (enExample)
IE (1) IE54371B1 (enExample)
IL (1) IL66992A (enExample)
IT (1) IT1153265B (enExample)
LU (1) LU88327I2 (enExample)
MX (2) MX166499B (enExample)
MY (1) MY102546A (enExample)
NL (1) NL930040I2 (enExample)
NO (2) NO164177C (enExample)
NZ (1) NZ202190A (enExample)
OA (1) OA07233A (enExample)
PH (1) PH26963A (enExample)
PL (1) PL153202B1 (enExample)
PT (1) PT75696B (enExample)
RO (1) RO89534A (enExample)
RU (3) RU2056460C1 (enExample)
SG (1) SG76988G (enExample)
SK (1) SK738982A3 (enExample)
YU (1) YU45871B (enExample)
ZA (1) ZA827569B (enExample)
ZW (1) ZW22282A1 (enExample)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
JPS62223191A (ja) * 1981-12-24 1987-10-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチドの製法
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US6432677B1 (en) 1982-03-08 2002-08-13 Genentech, Inc. Non-human animal interferons
US5827694A (en) * 1982-03-08 1998-10-27 Genentech, Inc. DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
AU571460B2 (en) * 1982-09-27 1988-04-21 Cancer Institute Of Japanese Foundation For Cancer Research Alpha interferon dna, recombinant plasmid, engineered organism and alpha interferon polypeptide
EP0121569B1 (en) * 1982-10-08 1990-08-22 Kyowa Hakko Kogyo Co., Ltd. Novel vector
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
WO1984002129A1 (fr) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (enExample) * 1982-12-22 1984-10-02 Genentech Inc
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
US7198919B1 (en) * 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
ZA843275B (en) * 1983-05-05 1984-12-24 Hoffmann La Roche Novel vectors for interferon expression
IL71951A0 (en) * 1983-06-01 1984-09-30 Hoffmann La Roche Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
JP2551746B2 (ja) * 1983-07-19 1996-11-06 サントリー株式会社 改良プラスミドベクタ−およびその利用
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
JPS6034919A (ja) * 1983-08-04 1985-02-22 Green Cross Corp:The ガンマ・インタ−フェロン組成物
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
GB8328820D0 (en) * 1983-10-28 1983-11-30 Searle & Co Synthetic human gamma interferon gene
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
JPS60145098A (ja) * 1984-01-09 1985-07-31 Suntory Ltd 糖付加ポリペプチドの製造法
WO1985004420A1 (fr) * 1984-03-29 1985-10-10 Takeda Chemical Industries, Ltd. Nouvel adn et son utilisation
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
GB8414354D0 (en) * 1984-06-05 1984-07-11 Biogen Nv Purifying protein
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
WO1985005618A1 (fr) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Procede de preparation de derives de l'interferon
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
JPS60262594A (ja) * 1984-06-11 1985-12-25 Kanegafuchi Chem Ind Co Ltd ヒトインタ−フエロン−γ
GB8414911D0 (en) * 1984-06-12 1984-07-18 Searle & Co Producing human gamma interferon
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
GB2164650A (en) * 1984-09-25 1986-03-26 Fujisawa Pharmaceutical Co Process for production of y-interferon
JPS6188875A (ja) * 1984-10-05 1986-05-07 Kanegafuchi Chem Ind Co Ltd ヒトインタ−フエロン−γ
DE3436638C2 (de) * 1984-10-05 1992-10-08 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
WO1986004067A1 (en) * 1984-12-27 1986-07-17 Suntory Limited Method for purifying an interferon
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
DE3689899T2 (de) * 1985-04-08 1994-09-15 Amgen Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US5104795A (en) * 1985-11-13 1992-04-14 Zoma Corporation Shortened phosphoglycerate kinase promoter
ATE85812T1 (de) * 1985-11-13 1993-03-15 Xoma Corp Verkuerzter phosphoglycerat-kinase-promotor.
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US6238889B1 (en) * 1986-12-16 2001-05-29 Dsm N.V. Molecular cloning and expression of the Pro8 isoform of human IL-3
US4939088A (en) * 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US6384194B1 (en) * 1987-12-16 2002-05-07 Dsm N.V. Expression and purification of human interleukin-3 and muteins thereof
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL90021A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Process for the production of interferon
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US20020168750A1 (en) * 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) * 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5112605A (en) * 1989-03-17 1992-05-12 Genentech, Inc. Temporal gamma-interferon administration for allergies
US5196191A (en) * 1989-03-17 1993-03-23 Genentech, Inc. Temporal gamma-interferon administration for allergies
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
EP0487298A3 (en) * 1990-11-21 1992-12-16 Schering Corporation Human gamma interferon antagonist/agonist screen
AU1268192A (en) * 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
WO1992013077A1 (en) * 1991-01-29 1992-08-06 Brigham And Women's Hospital A cDNA ENCODING THE TYPE I IODOTHYRONINE 5' DEIODINASE
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994003599A1 (fr) * 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994010296A1 (en) * 1992-11-03 1994-05-11 Oklahoma Medical Research Foundation Transglutaminase gene
DE69322289T2 (de) 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
EP1997900A3 (en) 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US20020168634A1 (en) * 1999-05-05 2002-11-14 Christine Marie Debouck Methods for identifiying genes essential to the growth of an organism
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
NZ506854A (en) 1998-04-02 2003-07-25 Genentech Inc Treatment of cardiac hypertrophy
AU4499399A (en) * 1998-07-16 2000-02-07 Novo Nordisk A/S Method of making proteins in transformed yeast cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL149267A0 (en) 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CN1318443C (zh) * 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
BR0115392A (pt) * 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
CN1604795B (zh) * 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
US20050079156A1 (en) * 2001-11-06 2005-04-14 Grace Wong Method of treating endometreosis
EP1450839A4 (en) * 2001-11-06 2009-06-24 Serono Lab METHOD OF TREATING BREAST CANCER THAT MEETS OESTROGENES
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
WO2003093417A2 (en) 2002-05-01 2003-11-13 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
AU2003239774A1 (en) 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004004643A2 (en) * 2002-07-03 2004-01-15 The Brighamn And Women's Hospital, Inc. Interferon gamma in the detection and treatment of angiomyolipomas
US7335743B2 (en) * 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
CA2585672A1 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
EP2364995A1 (en) 2004-12-23 2011-09-14 Molmed SpA Conjugation product
EP2311880A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
EA013118B1 (ru) * 2005-01-27 2010-02-26 Новиммун С.А. Антитела против интерферона-гамма и способы их применения
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN101896276A (zh) * 2007-11-28 2010-11-24 智能管公司 用于生物标本的收集、刺激、稳定化和分析的装置、系统和方法
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2446172C1 (ru) * 2011-03-24 2012-03-27 Общество С Ограниченной Ответственностью "Фармапарк" Способ получения зрелого интерферона альфа-2 человека с использованием дрожжей saccharomyces cerevisiae и штамм-продуцент интерферона альфа-2 человека (варианты)
EA023379B1 (ru) * 2011-06-21 2016-05-31 Общество С Ограниченной Ответственностью "Фарма Ген" ШТАММ ESCHERICHIA COLI BL21(DE3)-pIE-GAMMA И СПОСОБ ПОЛУЧЕНИЯ ПРЕПАРАТА НАТИВНОГО РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА ГАММА ЧЕЛОВЕКА
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
LT2802606T (lt) 2012-01-10 2018-10-10 Biogen Ma Inc. Terapinių molekulių transporto per kraujo-smegenų barjerą padidinimas
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
EP3608401A1 (en) 2012-07-05 2020-02-12 Ohio State Innovation Foundation Compositions and methods related to viral vaccines
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US11761951B2 (en) 2015-02-04 2023-09-19 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
UY36550A (es) 2015-02-04 2016-08-31 Roche Innovation Ct Copenhagen As Oligómeros antisentido de tau y sus usos
BR112017023867A2 (pt) 2015-05-07 2018-07-24 Novimmune Sa métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
EP3344290A4 (en) 2015-08-31 2019-02-27 Technovax, Inc. VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV)
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3526332B1 (en) 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
CA3045650A1 (en) 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11672877B2 (en) 2017-08-23 2023-06-13 Wayne State University In vivo immunoimaging of interferon-gamma
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
BR112020014525A2 (pt) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
US12331076B2 (en) 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
BR112022018615A2 (pt) 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
AU2021250709A1 (en) 2020-03-30 2022-10-13 Trizell Ltd. Compositions and methods for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
US4376821A (en) * 1981-04-17 1983-03-15 Meloy Laboratories, Inc. Production of human IFN-gamma (immune) interferon
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna

Also Published As

Publication number Publication date
IT1153265B (it) 1987-01-14
LU88327I2 (fr) 1994-05-04
GR78391B (enExample) 1984-09-27
FR2514783B1 (fr) 1985-11-29
RU2056460C1 (ru) 1996-03-20
US4727138A (en) 1988-02-23
DE19375065I2 (de) 2004-07-01
GB2107718B (en) 1985-11-20
DE77670T1 (de) 1987-09-03
PL238671A1 (en) 1983-07-18
PH26963A (en) 1992-12-28
US4762791A (en) 1988-08-09
BR8206068A (pt) 1983-09-13
EP0077670B1 (en) 1989-06-28
NO1994025I1 (no) 1994-12-20
RU2092561C1 (ru) 1997-10-10
NZ202190A (en) 1987-06-30
EP0077670A2 (en) 1983-04-27
YU45871B (sh) 1992-09-07
PT75696B (en) 1987-03-24
GT198277746A (es) 1984-04-11
MX166499B (es) 1993-01-12
DE3238554C2 (enExample) 1989-11-23
IE54371B1 (en) 1989-09-13
DE3238554A1 (de) 1983-05-05
PT75696A (en) 1982-11-01
IT8223795A0 (it) 1982-10-18
DK163187C (da) 1992-06-22
AU8935282A (en) 1983-04-28
FI823528L (fi) 1983-04-20
SK279535B6 (sk) 1998-12-02
FR2514783A1 (fr) 1983-04-22
JPS5890514A (ja) 1983-05-30
KR840001837A (ko) 1984-06-07
AU561343B2 (en) 1987-05-07
ES8402351A1 (es) 1984-02-01
ZW22282A1 (en) 1983-05-11
HU202287B (en) 1991-02-28
OA07233A (fr) 1984-04-30
MY102546A (en) 1992-07-31
HK66289A (en) 1989-08-25
SG76988G (en) 1989-03-23
JPS62265986A (ja) 1987-11-18
US4925793A (en) 1990-05-15
ATE44289T1 (de) 1989-07-15
EP0077670A3 (en) 1984-07-04
NO823467L (no) 1983-04-20
YU233582A (en) 1985-03-20
DK460882A (da) 1983-05-27
FI823528A0 (fi) 1982-10-15
NO164177C (no) 1990-09-12
JPH03246232A (ja) 1991-11-01
RU2107728C1 (ru) 1998-03-27
CH663619A5 (de) 1987-12-31
CZ738982A3 (en) 1997-03-12
NL930040I2 (nl) 1993-09-16
PL153202B1 (en) 1991-03-29
DE3279788D1 (en) 1989-08-03
BG44877A3 (bg) 1989-02-15
IT8223795A1 (it) 1984-04-18
RO89534A (ro) 1986-07-30
DZ467A1 (fr) 2004-09-13
NL930040I1 (nl) 1993-08-02
GB2107718A (en) 1983-05-05
JPH07106144B2 (ja) 1995-11-15
BG42527A3 (en) 1987-12-15
IE822517L (en) 1983-04-19
IL66992A0 (en) 1983-02-23
JPH0135639B2 (enExample) 1989-07-26
MX9206041A (es) 1994-04-29
FI86559B (fi) 1992-05-29
US4929554A (en) 1990-05-29
CZ282154B6 (cs) 1997-05-14
ES516620A0 (es) 1984-02-01
ZA827569B (en) 1983-11-30
IL66992A (en) 1991-07-18
CA1341590C (en) 2009-02-03
DD208822A5 (de) 1984-04-11
DK163187B (da) 1992-02-03
NO164177B (no) 1990-05-28
FI86559C (fi) 1992-09-10
JP2515308B2 (ja) 1996-07-10

Similar Documents

Publication Publication Date Title
SK738982A3 (en) Human immune interferon and derivative thereof, dna-fragment, replicable expression vector, a recombinant microorganism or a cell culture, pharmaceutical composition and use thereof
US5096705A (en) Human immune interferon
US5582824A (en) Recombinant DES-CYS-TYR-CYS human immune interferon
KR910001809B1 (ko) Csf 단백질 생산방법 및 정제방법
US4853332A (en) Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
FI80720C (fi) Saccharmyces cerevisiae-hybridvektorer och deras anvaendning foer framstaellning av plypeptider.
US6610830B1 (en) Microbial production of mature human leukocyte interferons
EP0158198A1 (en) DNA and use thereof
EP0041313A2 (en) DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon
WO1985005618A1 (fr) Procede de preparation de derives de l'interferon
HRP950157A2 (en) Polypeptide with human interferon (ifn-gamma) characteristics
BG61060B2 (bg) Човешки имунен интерферон
KR890001828B1 (ko) 인터페론-α형의 폴리펩티드의 제조방법
PH26492A (en) Recombinant human immune interferon
BG60889B2 (bg) Човешки имунен интерферон
BG60888B2 (bg) Човешки имунен интерферон
NZ214261A (en) Human immune interferon: production by recombinant dna technology
BG60939B2 (bg) Човешки имунен интерферон
BG60890B2 (bg) Човешки имунен интерферон
JPH08245695A (ja) 抗腫瘍活性物質